ADMA Biologics (NASDAQ:ADMA) Downgraded to "Strong Sell" Rating by Zacks Research

Key Points

• Zacks Research downgraded ADMA Biologics to “strong sell” from “hold,” while broader analyst coverage remains mixed. The stock has a consensus “hold” rating and an average price target of $18.67.
• ADMA reported quarterly EPS of $0.16, matching estimates, while revenue reached $124.39 million, up 2% year over year but slightly below consensus. The stock opened at $9.26 and was recently trading near the lower end of its 12-month range.
• Management reiterated 2026 revenue guidance of $530 million to $560 million and plans to repurchase more than $200 million of shares, but the company also faces potential legal and reputational risks from a promoted securities-fraud class action.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a report issued on Tuesday,Zacks.com reports.

ADMA has been the subject of several other reports. Mizuho decreased their target price on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Wall Street Zen downgraded ADMA Biologics from a "buy" rating to a "hold" rating in a research report on Monday, May 4th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Raymond James Financial began coverage on ADMA Biologics in a report on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 price objective for the company. Finally, Canaccord Genuity Group lowered their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $18.67.

ADMA Biologics Trading Up 3.9%

NASDAQ:ADMA opened at $9.26 on Tuesday. ADMA Biologics has a 12 month low of $7.21 and a 12 month high of $20.46. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of 13.62 and a beta of 0.74. The firm has a fifty day simple moving average of $8.55 and a two-hundred day simple moving average of $11.37. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts' consensus estimates of $0.16. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period in the prior year, the business earned $0.14 EPS. The firm's revenue for the quarter was up 2.0% on a year-over-year basis. Analysts expect that ADMA Biologics will post 0.8 EPS for the current fiscal year.

Insider Activity

In other ADMA Biologics news, Director Jerrold B. Grossman purchased 12,500 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the transaction, the director directly owned 513,884 shares of the company's stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.90% of the stock is owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Global Investments bought a new position in ADMA Biologics in the 2nd quarter worth about $155,000. Handelsbanken Fonder AB increased its holdings in ADMA Biologics by 27.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 98,800 shares of the biotechnology company's stock worth $827,000 after buying an additional 21,000 shares in the last quarter. Western Wealth Management LLC purchased a new position in ADMA Biologics in the 1st quarter worth about $31,000. Bank of America Corp DE lifted its stake in ADMA Biologics by 107.5% during the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company's stock valued at $36,019,000 after acquiring an additional 2,071,338 shares during the period. Finally, Amundi raised its holdings in shares of ADMA Biologics by 62.9% during the first quarter. Amundi now owns 51,761 shares of the biotechnology company's stock valued at $466,000 after purchasing an additional 19,985 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported second-quarter revenue of $124.4 million, up 2% year over year, while GAAP net income rose 11% to $37.8 million. Adjusted EBITDA increased 22% to $61.8 million, supporting the company’s profitability profile. ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Quarterly EPS met the $0.16 analyst consensus, and ASCENIV revenue climbed 24% to $102.9 million. Management also said BIVIGAM demand and revenue stabilized sequentially, indicating improving utilization trends. ADMA Biologics Q2 Earnings Snapshot
• Positive Sentiment: The company reiterated 2026 revenue guidance of $530 million to $560 million, broadly consistent with the $534.9 million consensus estimate, and is targeting more than $200 million in share repurchases. Buybacks could provide demand for the stock and increase per-share value if executed. ADMA Reiterates 2026 Guidance and Targets Share Repurchases
• Neutral Sentiment: Management highlighted new real-world evidence on ASCENIV’s patient outcomes and healthcare-resource utilization, potentially supporting longer-term demand, although the evidence remains an upcoming catalyst rather than a reported financial result.
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action covering investors who purchased ADMA securities from August 9, 2024, through March 25, 2026. The complaints allege misleading statements involving revenue, financial condition, inventory distribution and business practices. Lead-plaintiff notices cite an August 10 deadline. The allegations have not been proven, but the litigation creates legal costs, reputational risk and potential financial exposure. ADMA Securities Fraud Lawsuit Notice

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source